SCHEMBL166758

SCHEMBL166758

CCOC(=O)CC(O)(CC(=O)OC(C)=O)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
TRPA1 O75762 1/20 0.36
SOAT1 P35610 1/20 0.34
HSD11B1 P28845 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
CYP1A2 P05177 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
TSHR P16473 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethyl Citrate SCHEMBL28306859 0.89 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL73474 0.89 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL8107357 0.89 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10TSHRMAPT
SCHEMBL27677366 0.87 ALDH1A1 (0.31) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL14164382 0.87 ALDH1A1 (0.46) ALDH1A1HSD17B10TSHRCYP2C19
SCHEMBL28784375 0.87 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10GAAMGAM
Ammonia Solution, Strong SCHEMBL28679472 0.87 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL2118956 0.87 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10GAAMGAM
SCHEMBL9728575 0.87 ALDH1A1 (0.46) ALDH1A1HSD17B10TSHRCYP2C19
SCHEMBL28189565 0.87 ALDH1A1 (0.46) ALDH1A1HSD17B10TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113425696-B Effervescent preparation of compound oral rehydration salt and preparation process and application thereof 上海耀大生物科技有限公司 2022-09-02 CN claimed
CN-111298667-B Polymer-based blended film, and preparation method and application thereof 中国科学院大连化学物理研究所 2021-12-07 CN claimed
CN-113425696-A Effervescent preparation of compound oral rehydration salt and preparation process and application thereof 上海耀大生物科技有限公司 2021-09-24 CN claimed
CN-107955350-B Full-biodegradable drug-resistant mulching film composition and preparation method thereof 山东天野生物降解新材料科技有限公司 2020-07-21 CN claimed
CN-111298667-A Polymer-based blended film, and preparation method and application thereof 中国科学院大连化学物理研究所 2020-06-19 CN claimed
CN-107936507-B Mulching film for inhibiting weed growth and preparation method thereof 山东天野生物降解新材料科技有限公司 2020-01-14 CN claimed
EP-2623096-B1 Pharmaceutical composition with slow release of trimetazidine SERVIER LAB (FR) 2019-04-03 EP claimed
US-10117838-B2 Pharmaceutical composition for the prolonged release of trimetazidine LES LABORATOIRES SERVIER (FR) 2018-11-06 US claimed
WO-2018033621-A1 COMPOSITION FOR PREPARING AN ELECTROCHROMIC LAYER BASF SE (DE) 2018-02-22 WO claimed
CN-103456983-B Solid thin film electrolyte material and preparation method thereof 桂林电子科技大学 2016-10-19 CN claimed
US-20130202710-A1 PHARMACEUTICAL COMPOSITION FOR THE PROLONGED RELEASE OF TRIMETAZIDINE LES LABORATOIRES SERVIER (FR) 2013-08-08 US claimed
US-6983801-B2 Well treatment fluid compositions and methods for their use BJ SERVICES COMPANY (US) 2006-01-10 US claimed
US-20050016733-A1 Well treatment fluid compositions and methods for their use COMBINED SYSTEMS, INC. 2005-01-27 US claimed
US-6793018-B2 Solvent (such as water), a polymer soluble or hydratable in the solvent, a crosslinking agent such as a borate, an inorganic breaking agent, and an ester such as acetyl triethyl citrate; initial high viscosity, then low viscosity BJ SERVICES COMPANY 2004-09-21 US claimed
US-20020125012-A1 Well treatment fluid compositions and methods for their use BJ SERVICES COMPANY 2002-09-12 US claimed
WO-2002055843-A1 WELL TREATMENT FLUID COMPOSITIONS AND METHODS FOR THEIR USE BJ SERVICES COMPANY (US) 2002-07-18 WO claimed
EP-4419510-B1 NOVEL TRIMETAZIDINE SALTS SERVIER LAB (FR) 2025-10-08 EP disclosed
US-20250250245-A1 TRIMETAZIDINE SALTS LES LABORATOIRES SERVIER (FR) 2025-08-07 US disclosed
WO-2012028698-A1 MESALAZINE TABLET HAVING IMPROVED DISSOLUTION DISPHAR INTERNATIONAL B.V. (NL) 2012-03-08 WO disclosed
US-5134138-A ANTIBIOTICS SHIONOGI & CO., LTD. (JP) 1992-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250245-A1 TRIMETAZIDINE SALTS TRIM4, NNMT, NOX5 ALDH1A1 207/4885LMNA 3141/4885HSD17B10 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.